28th ANNUAL HENRY KUNKEL SOCIETY MEETING
IN PARTNERSHIP WITH JOURNAL OF EXPERIMENTAL MEDICINE (JEM) &
THE ROCKEFELLER UNIVERSITY FRIDAY LECTURE SERIES (FLS)
COMMITTEE

Thursday, March 18th - Saturday, March 20th, 2021

The Rockefeller University, New York, NY (virtually hosted)

Theme: New Dimensions of Therapeutic Antibodies

Meeting Chairs: Michel C. Nussenzweig, MD, PhD & Jeffrey V. Ravetch, MD, PhD
HKS President: Jean-Laurent Casanova, MD, PhD
JEM Executive Editor: Teodoro Pulvirenti, PhD
FLS Chair: Luciano Marraffini, PhD

Thursday, March 18, 2021

(Note: all times are US EST)

12:00 p.m.  Welcoming Remarks
Jean-Laurent Casanova, MD, PhD, President, Henry Kunkel Society

12:05 p.m. - 4:20 p.m.  Session I: Antibodies in Inflammation and Immuno-Oncology

12:05 p.m.  Barry P. Sleckman, MD, PhD
University of Alabama, Birmingham, AL, USA
SERCA Function in V(D)J Recombination and Lymphocyte Development

12:30 p.m.  Hedda Wardemann, PhD
German Cancer Research Center, Heidelberg, Germany
Single-cell based functional immune receptor repertoire studies for malaria vaccine design

12:55 p.m.  Claude-Agnes Reynaud, PhD
Institut Necker-Enfants Malades, Paris, France
Therapeutic outcomes in immune thrombocytopenia reveal multiple pathogenic B cell subsets

1:20 p.m.  Richard Blumberg, MD
Brigham & Women's Hospital, Boston, MA, USA
The (not so) neonatal Fc receptor and its immunologic functions

1:45 p.m.  Virginia Pascual, MD
Druker Institute at Weill Cornell Medicine, New York, NY, USA
Red Blood Cells: a Trojan Horse in SLE

2:15 p.m.  Break until 2:40 p.m.

2:40 p.m.  Boris Reizis, PhD
NYU Langone Medical Center, New York, NY, USA
Novel targets of autoreactivity in lupus

3:05 p.m.  Mark Jay Shlomchik, MD, PhD
University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Extrafollicular and GC Responses in Immunity and Autoimmunity
3:30 p.m. Betty Diamond, MD  
The Feinstein Institute for Medical Research, Manhasset, NY  
*Antibodies and neuropsychiatric disease: mechanisms, therapy and prevention*

3:55 p.m. Christopher Goodnow, PhD  
Garvan Institute of Medical Research, Darlinghurst, Australia  
*Mutations driving rogue clones to produce pathogenic rheumatoid factor autoantibodies*

4:20 p.m. Break until 4:50 p.m.

4:50 p.m. – 5:40 p.m. *Session II: Antibodies in immuno-ocology*

4:50 p.m. Falk Nimmerjahn, PhD  
University of Erlangen-Nuremberg, Erlangen, Germany  
*Organ specific pathways of cytotoxic IgG activity*

5:15 p.m. Fabienne Mackay, PhD  
University of Melbourne, Victoria, Australia  
*A novel cytokine-controlled immune checkpoint in chronic lymphocytic leukaemia*

Friday, March 19, 2021

9:00 a.m. Introduction for Annual Memorial Lecture  
Jeffrey V. Ravetch, MD, PhD

9:05 a.m. Tadatsugu Taniguchi, PhD  
The University of Tokyo, Tokyo, Japan  
*Annual Kunkel Memorial Lecture*  
*La storia mia è breve…*

10:15 a.m. Break until 10:40 a.m.

10:40 a.m. – 2:45 p.m. *Session III: Affinity Maturation and Selection*

10:40 a.m. Marina Caskey, MD  
The Rockefeller University, New York, NY, USA  
*Immunotherapy against HIV-1*

11:05 a.m. Carl Davis, MD, PhD  
Emory University, Atlanta, GA, USA  
*Public clonotypes in the B-cell response to Ebola virus*

11:30 a.m. Malcolm Martin, MD  
National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA  
The Use of Anti-HIV-1 Broadly Neutralizing Antibodies (bNAbs) for Prevention and Treatment of SIV/HIV Chimeric Virus (SHIV) Infections of Rhesus Macaques

11:55 a.m. Peter Palese, PhD  
Icahn School of Medicine at Mount Sinai, New York, NY, USA  
The long road to a universal influenza virus vaccine

12:20 p.m. Break until 1:30 p.m.

1:30 p.m. Taia T. Wang, MD, PhD  
Stanford University School of Medicine, Stanford, CA, USA  
*Signaling by antibodies in infection*
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:55 p.m.</td>
<td>Ian Wilson, DPhil</td>
<td>The Scripps Research Institute, San Diego, CA, USA</td>
<td>Structural insights into antibody responses to SARS-CoV-2 and escape mutations</td>
</tr>
<tr>
<td>2:20 p.m.</td>
<td>Patrick C. Wilson, PhD</td>
<td>The University of Chicago, Chicago, IL, USA</td>
<td>Human B cell memory in context</td>
</tr>
<tr>
<td>2:45 p.m.</td>
<td></td>
<td>Break until 3:15 p.m.</td>
<td></td>
</tr>
<tr>
<td>3:15 p.m.</td>
<td><strong>Session IV: Novel Platforms</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:15 p.m.</td>
<td>Richard Flavell, PhD</td>
<td>Yale School of Medicine, New Haven, CT, USA</td>
<td>Modeling the role of antibodies in COVID Pathogenesis</td>
</tr>
<tr>
<td>3:40 p.m.</td>
<td>Antonio Lanzavecchia, MD</td>
<td>Vir Biotechnology, Inc., San Francisco, CA, USA</td>
<td>Immunology taught by parasites</td>
</tr>
<tr>
<td>4:05 p.m.</td>
<td>Michael Lenardo, MD</td>
<td>National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA</td>
<td>Genetic basis of new immunoregulatory disorders</td>
</tr>
<tr>
<td>4:30 p.m.</td>
<td>Carola Vinuesa, MD, PhD</td>
<td>Australian National University, Canberra, Australia</td>
<td>Novel monogenic causes of human autoimmunity</td>
</tr>
</tbody>
</table>

**Saturday, March 20, 2021**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 a.m.</td>
<td><strong>Session V: Affinity Maturation and Selection</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 a.m.</td>
<td>Michael C. Carroll, PhD</td>
<td>Harvard Medical School, Boston, MA, USA</td>
<td>Evolution of auto-reactive Germinal center B cell</td>
</tr>
<tr>
<td>9:25 a.m.</td>
<td>Rafael C. Casellas, PhD</td>
<td>National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, USA</td>
<td>Multimeric nanobodies from camelid mice prevent escape of SARS-CoV-2 variants</td>
</tr>
<tr>
<td>9:50 a.m.</td>
<td>Michel Cogné, MD, PhD</td>
<td>Limoges University, Limoges, France</td>
<td>Unconventional tricks of human class-switching B-cells</td>
</tr>
<tr>
<td>10:15 a.m.</td>
<td>Gabriel Victora, PhD</td>
<td>The Rockefeller University, New York, NY, USA</td>
<td>Clonal dynamics of the antibody response</td>
</tr>
<tr>
<td>10:40 a.m.</td>
<td>Hao Wu, PhD</td>
<td>Boston Children's Hospital, Boston, MA, USA</td>
<td>Innate immunity, structural biology and human diseases</td>
</tr>
<tr>
<td>11:05 a.m.</td>
<td></td>
<td>Break until 11:35 a.m.</td>
<td></td>
</tr>
<tr>
<td>11:35 a.m.</td>
<td><strong>VI. Antibodies against cancers and prion diseases</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:35 a.m.</td>
<td>Eric Vivier, PhD</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
12:00 p.m.  Adriano Aguzzi, MD, PhD  
University of Zurich, Zurich, Switzerland  
Rationally designed neuroprotective antibodies against prions

12:25 p.m. - 12:40 p.m. Session VI: Memories of Henry Kunkel's Life

12:25 p.m.  Robert J. Winchester, MD  
Columbia University College of Physicians and Surgeons, New York, NY, USA  
Memories of Henry and life in the Kunkel lab

12:40 p.m.  Closing Remarks  
Jean-Laurent Casanova, MD, PhD